London
· Delayed Price · Currency is GBP · Price in EUR Inventiva Company Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally.
It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France.
| Country | France |
| Founded | 2011 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Frederic Cren |
Contact Details
Address: 50 rue de Dijon Daix, 21121 France | |
| Phone | 33 3 80 44 75 00 |
| Website | inventivapharma.com |
Stock Details
| Ticker Symbol | 0RNK |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013233012 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pierre Broqua Ph.D. | Co-Founder, Chief Scientific Officer and Deputy Chief Executive Officer |
| Frederic Cren | Co-Founder, Chief Executive Officer and Director |
| Jean Volatier | Deputy GM and Chief Financial Officer |
| Alice Roudot-Ketelers Pharm.D. | Chief Operating Officer |
| Eric Duranson L.L.M. | General Counsel |
| Nathalie Harroy | Head of Human Resources |
| Dr. Kristina Meyer Ph.D. | Executive Vice President and Business Development and Alliance Management |
| Dr. Michael Cooreman | Chief Medical Officer |
| Pascaline Clerc Ph.D. | Executive Vice President of Strategy and Corporate Affairs |